Explore every episode of the podcast The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin, after a three-year regulatory journey. Plus Novartis bets $2B on a next-gen Xolair successor, Otsuka acquires Transcend for $700M upfront, andAstraZeneca's tozorakimab delivers dual Phase 3 wins in COPD. Rocket Pharmaceuticals lands its first gene therapy approval for severe LAD-I.

Visit us at: www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Awiqli, insulinicodec, Novo Nordisk, FDA approval, once-weekly insulin, diabetes, Novartis, Excellergy, Xolair, Otsuka, Transcend Therapeutics, PTSD, neuropsychiatry, CVCCapital, Recordati, AstraZeneca, tozorakimab, COPD, Rocket Pharmaceuticals,KRESLADI, gene therapy, LAD-I, Sarclisa, Sanofi, CHMP, M&A, deals, Lilly, J&J, GSK

Wave Life Sciences plunges 58% after WVE-007 higher-doseobesity data fails to separate from lower dose. CVC Capital Partners offers €52/share ($12.6B) to take Recordati private. Plus: Kodiak's Phase 3 GLOW2 diabetic retinopathy win, Corcept's relacorilant approval in ovarian cancer, and FDA "America First" user fee pushback.

Visit us at: www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Wave Life Sciences, WVE-007, obesity drug data, INLIGHT trial, Recordati, CVC Capital Partners, rare disease, take-private, Kodiak Sciences, tarcocimab, Zenkuda, GLOW2,diabetic retinopathy, Corcept Therapeutics, relacorilant, Lifyorli, ovarian cancer, Denali, Avlayah, Hunter syndrome, Alnylam, ATTR, user fees, America First, Pinnacle Medicines, oral peptide, M&A, Takeda

Structure's aleniglipron delivers 16.3% weight loss in Phase2 — challenging Lilly's orforglipron in the oral GLP-1 race. Plus BioMarin's Voxzogo safety halt, Aldeyra's reproxalap FDA decision, Rhythm's EMANATE miss ahead of Thursday PDUFA, and Bayer's Kerendia CKD expansion win.

Visit us at https://thepharmacloseout.com/

#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Structure Therapeutics, #aleniglipron, #GLP-1, #oral obesity, #BioMarin, #Voxzogo, #achondroplasia, #Aldeyra, #reproxalap, #dry eye, #Rhythm Pharmaceuticals, #Imcivree, #EMANATE, #Bayer, #Kerendia, #finerenone, #CKD, #CytomX, #varsetatug masetecan, #ADC, #colorectal cancer, #Eli Lilly, #Ebglyss, #atopic dermatitis, #GSK, #Amgen, #TrumpRx, #CDC vaccine schedule, #PDUFA, #Pfizer, #Lilly, #Merck, #J&J, #Sanofi

Immutep's LAG-3 drug eftilagimod alfa fails Phase 3 futility analysis in NSCLC—stock drops 88%. Ultragenyx DTX301 gene therapy hits co-primary endpoint in OTC deficiency. Plus: Lilly's $3B orforglipron manufacturing expansion, BridgeBio muscular dystrophy data, and four PDUFA dates ahead.

Visit at: https://thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Immutep, eftilagimod alfa, LAG-3, NSCLC, Ultragenyx, DTX301, OTC deficiency, gene therapy, Eli Lilly, orforglipron, China manufacturing, BridgeBio, BBP-418, muscular dystrophy, GSK, Arexvy, RSV vaccine, Biogen, salanersen, SMA, Roche, giredestrant, Aldeyra, reproxalap, Rhythm Pharmaceuticals, IMCIVREE, Rocket Pharmaceuticals, KRESLADI, Sandoz, biosimilars, AEMS, ACC 2026, Pfizer, Lilly, Merck, BMS, Gilead

GSK wins FDA clearance to expand Arexvy RSV vaccine to at-risk adults ages 18-49 — the broadest age indication in the RSV market. Plus: Novartis claims the only IL-17A approval for pediatric hidradenitis suppurativa, Pfizer shuts down its small biotech R&D support unit, and why manufacturing is the story to watch as the 2026 patent cliff approaches

Substack: https://thepharmacloseout.substack.comLinkedin: www.linkedin.com/company/the-pharma-closeout

#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #GSK, #Arexvy, #RSVvaccine, #FDA approval, #Novartis, #Cosentyx, #hidradenitis suppurativa, #Pfizer, #Ignite, #Gilead, #lenacapavir, #patent cliff, #Y-mAbs, radiopharmaceutical, #Hyloris, #Unixell, #cell therapy, #manufacturing, #Lilly, #Moderna

Ultragenyx's gene therapy clears pivotal trial for raremetabolic disease — a critical win for the gene therapy sector. Lilly invests $3B in China manufacturing for oral GLP-1 and escalates the compounding fight. LAG-3 pioneer fails Phase 3, raising hard questions about the immuno-oncology target. Plus: GSK Arexvy wins expanded RSV approval.

Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠

Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠

#pharma, #pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Ultragenyx, #genetherapy, #urea cycle disorder, #Eli Lilly, #orforglipron, #GLP-1, #tirzepatide,#compounding pharmacies, #LAG-3, #immuno-oncology, #checkpoint inhibitor, #GSK,#Arexvy, #RSV vaccine, #rare disease, #orphan drugs, #Pfizer, #Lilly, #Roche

Three competitive strategies. A $135.7 billion Chineseout-licensing signal. Three diverging regulatory frameworks. We pull together everything from the series into a practical framework: which companies arepositioned to win, which strategic models carry the most risk, and what every pharma professional should be doing right now.

Substack: ⁠https://thepharmacloseout.substack.com⁠Linkedin: ⁠www.linkedin.com/company/the-pharma-closeout⁠

#pharma, #AI strategy, #competitive advantage, #China pharma, #cross-border licensing, #FDA, #EMA, #NMPA, #regulatory divergence, #Eli Lilly, #Recursion, #GSK, #build vs buy

Vertex clears Phase 3 in kidney disease as after-hoursshares surge. Plus Lilly commits $3B to China GLP-1 manufacturing, UCB's Bimzelx defeats AbbVie's Skyrizi head-to-head, and an FDA approval for fewer than 50 patients worldwide. Wednesday's essential pharma intelligence.

#pharma, pharmaceutical, #FDA, #clinical trials, #biotech, drug approvals, #healthcare, #pharma podcast, #The Pharma #Closeout, #Vertex, #kidney disease, #Eli Lilly, #China manufacturing, #GLP-1, #UCB, #Bimzelx, #AbbVie, #Skyrizi,#psoriatic arthritis, #GSK, #leucovorin, #cerebral folate deficiency, #Bristol Myers, #mezigdomide, #multiple myeloma, #Xenon, #epilepsy, #BioNTech, #mRNA, #Roche,#giredestrant, #Lilly

BioNTech's co-founders just walked away. Both of them. Sameday. They're starting a new mRNA company from scratch. And the FDA approved a drug today without running a clinical trial. That's not a typo — we'll explain the precedent.

#pharma, pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Pfizer, #Lilly, #Novo Nordisk, #Roche, #GSK, #Vertex

Tags

Novo Nordisk and Hims end legal battle, team up for branded GLP-1 telehealth distribution. BMS gets Sotyktu psoriatic arthritis approval and Phase 3 CELMoD win. Incyte receives CRL due to Novo's Indiana manufacturingissues — third company hit by same facility.

#pharma,# pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Novo Nordisk, #Hims& Hers, #GLP-1, #semaglutide, #Ozempic, #Wegovy, #obesity, #telehealth, #Bristol Myers Squibb, #Sotyktu, #deucravacitinib, #psoriatic arthritis, #CELMoD, #Incyte,#CRL, #manufacturing, #Talkspace, #UHS, #Ipsen, #Tazverik, #Xenon, #epilepsy, #Lilly, #GSK, #BMS

Agentic AI is moving from augmenting human work to acting autonomously — monitoring supply chains, adjusting production parameters, generating medical information responses. The EBITDA projections are enormous. So are the risks when an AI agent touches patients. We walk through the deployments, the economics, and the governance gap.

#pharma, #agentic AI, #commercial operations, #manufacturing, #digital twins, #supply chain, #EBITDA, #governance, #EU AI Act, #Novo Nordisk, #GSK, #Pfizer

This week, the pharma industry stacked three of the year's biggest deals in five days — and the FDA quietly told us something important about what happens when gene therapy evidence packages get thin. Meanwhile, the GLP-1 wars got more expensive for everyone not named Novo or Lilly. Let's take it apart.

Merck pays $6.7B for Terns Pharmaceuticals and its CMLcandidate TERN-701 as the Keytruda patent cliff nears. FDA approves Denali's Avlayah — the first biologic designed to cross the blood-brain barrier — for Hunter syndrome, and Corcept's Lifyorli (relacorilant) for platinum-resistantovarian cancer. Plus Ionis cuts Tryngolza's price 93%.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Merck, Terns Pharmaceuticals, TERN-701, chronic myeloid leukemia, CML, Keytruda, Denali Therapeutics, Avlayah, Hunter syndrome, MPS II, Corcept Therapeutics, Lifyorli,relacorilant, ovarian cancer, Ionis, Tryngolza, Beam Therapeutics, BEAM-302,Biogen, Alteogen, Novartis, Scemblix, Eli Lilly, Lilly, Novo Nordisk, Takeda

The FDA told uniQure it is not convinced AMT-130provides any therapeutic benefit in Huntington’s disease — the program now faces a full Phase Three, raising the evidentiary floor for all CNS gene therapy. Moderna jumped fourteen percent on forty-nine percent melanomarecurrence reduction from mRNA-4157 plus Keytruda, combined with resolution of its LNP patent overhang. Servier acquires Day One Biopharmaceuticals fortwo-and-a-half billion dollars; Zealand’s petrelintide obesity data triggers a thirty-five percent drop; Lantheus’s PYLARIFY TruVu wins FDA approval

Theravance Biopharma’s Phase 3 CYPRESS trial of ampreloxetine in neurogenic orthostatic hypotension fails to meet the primary OHSA endpoint at week 8. The company announces a 50% workforce reduction, shuts down R&D, and targets 60% cash burn reduction ($70M annual savings) as it pivots to Yupelri (revefenacin) as its sole commercial asset. Stock drops 26% from $18.95 to $13.96. Science Corporation closes a $230 million Series C at a $1.5 billion valuation for its PRIMA retinal brain-computer interface — 80% of patients in the NEJM-published trial showed meaningful visual acuity improvement. Roche commits $484 million over fiveyears to South Korea’s biopharma ecosystem. BMS Sotyktu psoriatic arthritis PDUFA is tomorrow, March 6. Lantheus PSMA PET imaging PDUFA also March 6.

Moderna agrees to pay up to $2.25 billion to settle the lipid nanoparticle patent dispute with GenevantSciences and Arbutus Biopharma — $950M upfront in July 2026, with $1.3B contingent on a government contractor immunity appeal under Section 1498. The settlement grants Moderna a global non-exclusive LNP license for infectious disease applications. FDA issues 30 warning letters to telehealth companies overcompounded GLP-1 marketing, its most aggressive enforcement action yet as the shortage-era legal basis for compounding erodes. GenoGenix manufacturingconcerns linked to three ER visits. BMS Sotyktu (deucravacitinib) PsA PDUFA Friday March 6 — Spherix survey shows 1 in 3 rheumatologists view it as substantial advance. GSK linerixibat PDUFA March 24 for PBC cholestatic pruritus. BridgeBio presents additional FORTIFY Phase 3 BBP-418 muscular dystrophy data at MDA conference.

173 AI-discovered drugs in clinical development. Phase 1 success rates of 80-90% vs 52% traditional. But at Phase 2, the AI advantage disappears — and nobody's talking about it. We unpack rentosertib's Nature Medicine data, zasocitinib's Phase 3 win, the Recursion pipeline reality, synthetic control arms cutting trial timelines by18 months, the FDA's 7-step AI credibility framework, and what this means for R&D careers. Episode 2 of "The AI Reckoning: Pharma's Make-or-Break Moment."

Novo Nordisk commits €432 million ($506M) to expand oral semaglutide tablet manufacturing in Athlone,Ireland — a supply bet on oral Wegovy’s trajectory as 246,000 patients are already on therapy. Morgan Stanley upgrades Novo from Underweight to Equal Weight,citing ~56% potential upside as a floor call, while Lilly holds a 21-point GLP-1 market share lead (60.5% vs 39.1%). Orforglipron’s Q2 FDA decision is the next test of whether Novo can hold the oral lane. BMS has a PDUFA on Friday for Sotyktu’s psoriatic arthritis indication — which would make deucravacitinib the first TYK2 inhibitor approved in PsA. Imcivree (March 20) and Kresladi (March 28) PDUFA dates round out a busy Q1 regulatory calendar.

Gilead acquires Arcellx for $7.8B to challenge J&J’s Carvykti in multiple myeloma with a December FDAdecision approaching. Both Friday decisions resolved: YUVIWEL wins accelerated approval as the first weekly achondroplasia treatment, Dupixent adds AFRS toits ENT franchise. PADCEV plus Keytruda delivers a 47% recurrence reduction in muscle-invasive bladder cancer. CagriSema analyst downgrades continue, and theMarch 20th Rhythm decision could reshape the obesity landscape.

Seven analyst downgrades, Deutsche Bank at Hold with a 275 DKK target, Morningstar cutting CagriSema peaksales from $13B to $8B. We cover the open-label design limitation constraining Novo's patient-reported outcome claims and where the differentiation argumenthas to go next. Plus GSK's $950M activin bet, China licensing at record pace, Lilly's ACHIEVE-3 win. FDA approved YUVIWEL with a $100–150M PRV. Dupixent'sninth indication. Pfizer/Astellas bladder cancer data that deserved more coverage. Week ahead: Imcivree Mar 20, Kresladi Mar 28, pelacarsen H1 readout.

Novo's CagriSema misses non-inferiority against Zepbound in REDEFINE 4 — approval path intact,differentiation argument shifts to outcomes data. GSK pays $950M for HS235 (35Pharma), a Phase 1 activin inhibitor targeting Merck's Winrevair territory.Lilly's ACHIEVE-3 puts orforglipron decisively ahead of oral semaglutide: 31.4% of patients to near-normal A1C vs 11.7%. Two FDA decisions today: TransCon CNP for achondroplasia and Dupixent's AFRS label expansion.

Only 5% of pharma companies have turned AI into competitive advantage. 89% of AI pilots fail to scale. The gap is widening, not closing. We unpack the $6.6B market reality, what "production scale" actually means vs. what companies claim, why 80% of AI transformation is organizational change not technology, the skills half-life crisis (2-5 years by 2030), and the board governance vacuum. Episode 1 of our 4-part special series "The AI Reckoning: Pharma's Make-or-Break Moment."

ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.

Visit us at: www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines, gamgertamig, BCMA CD3, bispecific antibody, autoimmune disease, UCB, Bimzelx, biologics manufacturing, Shionogi, Apnimed, Milestone Pharmaceuticals, etripamil, CARDAMYST, Rezolute,Karyopharm, Xpovio, MFN drug pricing, Eli Lilly, Ocugen, Lilly

Apogee's zumilokibart shows every-3-to-6-month dosing in atopic dermatitis, stock surges 20%+. Gilead nears $2B Ouro Medicines acquisition. Insmed Arikayce ENCORE Phase 3b hits primary endpoint in MAC lung disease. Dizal Zegfrovy pressures J&J's Rybrevant with first-line NSCLC data.

Follow us at: https://thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Apogee Therapeutics, zumilokibart, atopic dermatitis, eczema, Dupixent, Gilead, Ouro Medicines, Insmed, Arikayce, MAC lung disease, Dizal, Zegfrovy, sunvozertinib, Rybrevant, Sanofi, Kali Therapeutics, T cell engager, Aurinia, Kevin Tang, M&A, Lilly, Novartis, AstraZeneca, J&J, Regeneron

Abbott finalizes its ~$21B Exact Sciences acquisitionMonday, reshaping cancer diagnostics. Novo's Wegovy HD wins FDA approval as Lilly's orforglipron PDUFA slips to April 10. Plus: GSK's Lynavoy, Pfizer's TALAPRO-3 data, and Genentech's emugrobart setback. Full week-in-review.

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Abbott, Exact Sciences, Cologuard, Oncotype DX, Novo Nordisk, Wegovy HD, semaglutide,orforglipron, Eli Lilly, GSK, Lynavoy, linerixibat, PBC, Pfizer, talazoparib, TALAPRO-3, prostate cancer, camrelizumab, rivoceranib, HCC, Rhythm Pharmaceuticals, Imcivree, Novartis, PI3K, Genentech, emugrobart, RocketPharmaceuticals, Kresladi, Lantheus, AAD 2026, M&A, obesity, GLP-1, diagnostics, Lilly

Novartis pays $2B upfront for Synnovation's Phase 1/2 PI3Kα inhibitor SNV4818 to defend its HR+/HER2- breast cancer franchise. Plus: BMS Opdivo wins first immunotherapy combo approval in frontline Hodgkin lymphoma, GSK's Lynavoy becomes first drug for cholestatic pruritus in PBC, and Pfizer's TALAPRO-3 clears Phase 3 in prostate cancer.

Visit us at: https://thepharmacloseout.com/

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Novartis,Synnovation Therapeutics, PI3K alpha inhibitor, SNV4818, breast cancer, HR+HER2-, Bristol Myers Squibb, BMS, Opdivo, nivolumab, Hodgkin lymphoma, GSK,linerixibat, Lynavoy, primary biliary cholangitis, PBC, cholestatic pruritus,Pfizer, Talzenna, talazoparib, Xtandi, enzalutamide, prostate cancer,TALAPRO-3, Collegium, Azstarys, ADHD, Rhythm Pharmaceuticals, IMCIVREE, setmelanotide,Genentech, Roche, emugrobart, obesity, Earendil, AI biotech, Lilly

Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same day Novo's Wegovy HD wins record-fast CNPV approval. Plus Collegium acquires Azstarys for $650M, Pfizer's Talzenna wins in prostatecancer, and Lynavoy gets an early FDA nod.

Visit the website at: https://thepharmacloseout.com/

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, retatrutide, Eli Lilly, TRANSCEND-T2D-1, Wegovy HD, Novo Nordisk, semaglutide, CNPV, CollegiumPharmaceutical, Corium, Azstarys, ADHD, Pfizer, Talzenna, talazoparib,TALAPRO-3, prostate cancer, Lynavoy, linerixibat, Alfasigma, GSK, primary biliary cholangitis, CSL, Hemgenix, gene therapy, ACIP, AstraZeneca, Shanghai, obesity, Type 2 diabetes, GLP-1, triple agonist, PARP inhibitor, Lilly, Merck, Sanofi, Moderna

FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.

Follow us at: https://thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist Therapeutics, psoriasis, FDA approval, Bicycle Therapeutics, zelenectide, Padcev, Sandoz, Samsung Bioepis, biosimilar, Entyvio, Eli Lilly, HSBC, GLP-1, obesity, Crossbow Therapeutics,TerraPower, radiopharmaceutical, actinium-225, GSK, linerixibat, RMAT, Pfizer, Lilly, J&J, AbbVie, Takeda

Aldeyra Therapeutics crashes ~68% after the FDA rejectsreproxalap for the third time. CytomX jumps 60%+ on masked ADC data in colorectal cancer. Pfizer's atirmociclib shows 40% PFS reduction in post-CDK4/6 breast cancer. Plus: court blocks RFK Jr. vaccine overhaul, MFN pricingreshapes deal structures, and Bicycle retreats from Padcev.

Follow the podcast and visit our site at https://thepharmacloseout.com/#pharma,#pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma #Closeout, #Aldeyra#Therapeutics, #reproxalap, #CRL, #dry eye disease, #CytomX, #varsetatug masetecan, #masked ADC, #colorectal cancer, #Pfizer, #atirmociclib, #Ibrance, #CDK4, #breast cancer, #Bicycle Therapeutics, #Padcev, #Rhythm Pharmaceuticals, #Imcivree, #RFK Jr,vaccine policy, #most favored nation, #MFN, #drug pricing, #GSK, #linerixibat, #Merck, #Sanofi, #Moderna

Eli Lilly signs $2.75B biobucks deal with Insilico Medicinefor AI-discovered oral therapeutics. AAD 2026 brings 52-week ICOTYDE, zasocitinib Phase 3 psoriasis data, and Sanofi amlitelimab Q12W dosing in atopic dermatitis. Plus HI-PEITHO PE results from ACC and Merck's WINREVAIRCADENCE proof-of-concept.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, InsilicoMedicine, AI drug discovery, ICOTYDE, icotrokinra, zasocitinib, Takeda, Johnson Johnson, Sanofi, amlitelimab, sonelokimab, MoonLake, Boston Scientific, EKOS,HI-PEITHO, pulmonary embolism, WINREVAIR, sotatercept, Merck, Angelini Pharma,Recordati, CVC Capital Partners, AAD 2026, ACC 2026, psoriasis, atopic dermatitis, hidradenitis suppurativa, orforglipron, Orca-T, Lilly

Eli Lilly acquires Centessa Pharmaceuticals for up to $7.8B,targeting narcolepsy via orexin agonists as part of pharma's $25.5B eight-day buying spree. Biogen bets $5.6B on Apellis complement therapies. FDA warns of 8deaths linked to Amgen's Tavneos liver safety signal.

visit us at: www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, Centessa Pharmaceuticals, Biogen, Apellis Pharmaceuticals, Amgen, Tavneos, avacopan,orexin, narcolepsy, AstraZeneca, efzimfotase alfa, hypophosphatasia, Agios, mitapivat, sickle cell disease, Novo Nordisk, Wegovy, Merck, Infinimmune, M&A, acquisitions, Lilly

United Therapeutics' Tyvaso delivers 130.1 mL FVCimprovement in TETON-1, its second Phase 3 win in IPF — filing plans now underway. Plus Viridian's 38% stock crash on REVEAL-1 data, Lilly's $115M upfront AI deal with Insilico Medicine, BridgeBio's 54-month ATTR-CM survivaldata, Biogen's Spinraza HD FDA approval, and CBER untitled letters hitting four major companies.

Visit us at www.thepharmacloseout.com

Pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Tyvaso, treprostinil, United Therapeutics, IPF, idiopathic pulmonary fibrosis, TETON-1, Viridian Therapeutics, elegrobart, REVEAL-1, thyroid eye disease, Eli Lilly, Insilico Medicine, AI drug discovery, BridgeBio, acoramidis, ATTR-CM, Biogen, Spinraza, nusinersen, SMA, spinal muscular atrophy, Takeda, restructuring, Blackstone, CBER, untitled letters, BMS, Novartis, Gilead, Iovance, Kailera, obesity, GLP-1, Lilly, Amgen

Trump signs 100% tariffs on imported drugs — but exemptions create a two-tier system reshaping competitive modeling. $25.5B in pharmaM&A in eight days as R&D pipeline shrinks for first time in 30 years. Lilly's Foundayo approved, oral obesity war heats up. ORIC crashes on dose selection.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, drug tariffs, Section 232, Eli Lilly, Foundayo, orforglipron, Novo Nordisk, Wegovy, obesitydrugs, GLP-1, Biogen, Apellis, Centessa, Merck, Terns Pharma, ORIC Pharmaceuticals, rinzimetostat, CVR, contingent value rights, Pfizer, BioNTech,COVID vaccine, Gilead, HIV, Orca Bio, biopharma pipeline, pharmaceutical tariffs, reshoring, M&A, Blackstone, Ambrosia Biosciences, Lilly

Trump signs 100% tariff on imported branded drugs—exemptions create pharma haves and have-nots. Lilly's oral obesity pill Foundayo wins FDA approval as analysts project blockbuster launch. Lilly-Centessa ($6.3B) andBiogen-Apellis ($5.6B) deals cap a $25.5B acquisition spree.

visit us at: www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Trump pharma tariff, pharmaceutical tariffs, Eli Lilly, Foundayo, orforglipron, FDA approval, obesity drugs, GLP-1, Novo Nordisk, Centessa, Biogen, Apellis, CVR,AstraZeneca, EMERALD-3, liver cancer, Vertex, cystic fibrosis, Alyftrek, Trikafta, EYLEA HD, Regeneron, aflibercept, Lipocine, postpartum depression,Merck, Infinimmune, Blackstone, Ambrosia, M&A, drug pricing, Lilly, AbbVie, GSK, Amgen

Lilly's Foundayo becomes the first oral GLP-1 approved forobesity in the U.S. — LLY jumps 3.78%. Immunovant's batoclimab misses both Phase 3 endpoints in thyroid eye disease. Plus: Merck-Infinimmune $838M antibody deal, Blackstone's record $6.3B life sciences fund, and the WhiteHouse readies 100% tariffs on imported brand-name drugs.

www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo, orforglipron, Eli Lilly, obesity, GLP-1, oral obesity pill, FDA approval, Immunovant, batoclimab, thyroid eye disease, FcRn, Merck, Infinimmune, Blackstone, Cogent Biosciences, bezuclastinib, GIST, Cyclerion, Korsana, Novo Nordisk, Wegovy, PADCEV, KEYTRUDA, drug tariffs, Lilly, Roche, AstraZeneca, Sanofi, Amgen, Gilead, Vertex

Trump's 100% tariff on patented drugs reshapes pharmastrategy—tiered exemptions create winners and losers. Lilly's Foundayo approved; Novo fires back with ORION data showing oral Wegovy's tolerability edge. Plus Biogen-Apellis, Q1's $47B M&A wave, and the first R&Dpipeline contraction in 30 years.

visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, pharma tariff, Trump pharmaceutical tariff, Section 232, Foundayo, orforglipron, Eli Lilly, oral GLP-1, Novo Nordisk, oral Wegovy, semaglutide, ORION study, obesity drugs, Biogen, Apellis, CVR, contingent value rights, biopharma M&A, Orca-T, Orca Bio, Blackstone life sciences, R&D pipeline, Citeline, sparsentan, Travere,AXS-05, Axsome, AACR, AAN, Lilly, Merck

100% tariffs on branded drug imports took effect — but thecarve-outs may matter more than the rate. Gilead acquires ADC maker Tubulis for $3.15B upfront (up to $5B), Merck launches its $6B Terns tender offer after cutting the bid by $1B on data concerns, and Novo Nordisk rolls out Wegovy HD7.2mg nationwide. Plus FDA Commissioner Makary's FY2027 budget proposals and Corbus secures its CRB-701 registration path.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, pharma tariffs, Section 232, Gilead, Tubulis, ADC, antibody-drug conjugate, Merck, Terns Pharmaceuticals, Novo Nordisk, Wegovy HD, semaglutide, obesity, Amgen, Tepezza, teprotumumab, thyroid eye disease, Sanofi, lunsekimig, bispecific antibody, FDA budget, GeneriPreCheck, Corbus Pharmaceuticals, CRB-701, Nectin-4, AbbVie, Humira, TrumpRx, Neurocrine, Soleno, Prader-Willi syndrome, Travere, FILSPARI, FSGS, Roche, AstraZeneca

Gilead pays $3.15B for ADC specialist Tubulis — third dealin six weeks. Neurocrine bets $2.9B on Soleno for Prader-Willi, Merck reprices Terns by $1B after data peek, and Sanofi's bispecific lunsekimig hits in asthma but misses in eczema. Plus Novo launches high-dose Wegovy.

www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Gilead, Tubulis, ADC, antibody-drug conjugate, Neurocrine, Soleno, Prader-Willi, Vykat, Merck, Terns Pharmaceuticals, TERN-701, CML, Sanofi, lunsekimig, Amgen, Tepezza,teprotumumab, Novo Nordisk, Wegovy, semaglutide, AbbVie, Humira, TrumpRx, ImmunityBio, Anktiva, M&A, oncology, rare disease, Pfizer, Lilly, AstraZeneca

Lilly launches Foundayo to challenge Novo Nordisk in oralGLP-1s with a GoodRx access play. Gilead acquires ADC specialist Tubulis for $3.15B upfront in its third deal since February. Plus FDA lifts MacroGenics hold, AbbVie sues over 340B, and Vanda targets GLP-1 side effects with theThetis trial.

www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, Foundayo, oral GLP-1, Novo Nordisk, Gilead Sciences, Tubulis, ADC, antibody-drug conjugate, MacroGenics, lorigerlimab, Vanda Pharmaceuticals, tradipitant, Nereus, AbbVie, 340B, PhRMA, Steven Ubl, Roche, C4 Therapeutics,DAC, Garda, Assertio, Rolvedon, Kyverna, KYSA-8, Invivyd, measles, Shionogi, BARDA, GoodRx, Lilly, GSK, BMS, Gilead

Merck's Welireg misses in first-line RCC — Cantor challenges $2B+ peak sales. Lilly buys Kelonia for up to $7B in in vivo CAR-T push. Medicare indefinitely delays GLP-1 weight loss drug coverage pilot. Plus AstraZeneca IgAN data, Roche MOGAD results, Arrowhead upgrade.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Merck, Welireg, belzutifan, kidney cancer, renal cell carcinoma, Keytruda, Lenvima, Eisai, Eli Lilly, Kelonia Therapeutics, CAR-T, cell therapy, in vivo, AstraZeneca, Ultomiris, IgA nephropathy, Roche, Enspryng, MOGAD, satralizumab, Medicare, GLP-1, weight loss, Foundayo, Wegovy, Novo Nordisk, Arrowhead Pharmaceuticals, Plozasiran, Pfizer, UCB, Neurona, Replimune, Idvynso, HIV, Kailera, Tortugas, Nektar, BioAge, Carvykti, Lilly, J&J

Eli Lilly pays $3.25B upfront for Kelonia Therapeutics' invivo CAR-T platform in a deal worth up to $7B — the sixth buyout in this space since March 2025. Plus Gilead-Arcus TIGIT Phase 3 failure, Nektar's 20%+ alopecia surge, Trump's psychedelic executive order, AACR KRAS data from Revolution Medicines, and Novo Nordisk sickle cell Phase 3 results.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, KeloniaTherapeutics, in vivo CAR-T, cell therapy, TIGIT, Gilead, Arcus Biosciences,domvanalimab, Nektar Therapeutics, rezpegaldesleukin, alopecia areata,psychedelic drugs, ibogaine, Trump executive order, Revolution Medicines,zoldonrasib, KRAS, Merck, AACR 2026, Novo Nordisk, etavopivat, sickle celldisease, UCB, Neurona Therapeutics, Biogen, felzartamab, Kailera Therapeutics,IPO, Sanofi, Nuvaxovid, Novartis, Boehringer Ingelheim, PBM drug pricing,oncology, M&A, Lilly, Roche, BMS, Moderna

Allogene's cema-cel drives MRD negativity in 7 of 12lymphoma patients in Phase 3 Alpha3 — stock surges 50%+. Plus: Kailera's $625M biotech IPO, UCB's $1.2B Neurona acquisition for epilepsy cell therapy, Spyre'sbest-in-class UC data, Lilly Foundayo's launch metrics, and what to watch as AACR and Q1 earnings collide this week.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Allogene, cema-cel, CAR-T, allogeneic cell therapy, lymphoma, Kailera Therapeutics, IPO, UCB,Neurona Therapeutics, epilepsy, Spyre Therapeutics, SPY001, ulcerative colitis, Entyvio, Revolution Medicines, daraxonrasib, pancreatic cancer, Eli Lilly,Foundayo, orforglipron, AACR 2026, Novo Nordisk, GLP-1, zanidatamab, Obsidian Therapeutics, TIL therapy, Lilly, Moderna

Foundayo hits MACE-4 non-inferiority (HR 0.84) as Lillytargets diabetes filing by Q2 — but FDA requests liver risk data. Plus: Cochrane review dismisses anti-amyloid Alzheimer's drugs, Daiichi Sankyo divests $1.5B consumer health unit, and Kailera's $533M obesity IPO pricesahead of tomorrow's trading.

visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo,orforglipron, Eli Lilly, GLP-1, obesity, diabetes, ACHIEVE-4, MACE, Cochrane,Alzheimer's, lecanemab, donanemab, anti-amyloid, Kailera Therapeutics, IPO,Daiichi Sankyo, Suntory, Roche, Elevidys, Sarepta, Duchenne, RevolutionMedicines, Obsidian Therapeutics, CrossBridge Bio, ADC, UnitedHealth, Lilly,Novo Nordisk, AstraZeneca, Biogen

J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Johnson &Johnson, Tremfya, Stelara, Revolution Medicines, Beeline Medicines, BristolMyers Squibb, Bain Capital, Travere Therapeutics, Filspari, sparsentan, FSGS,Daiichi Sankyo, Suntory, Oric Pharmaceuticals, rinzimetostat, Foundayo,orforglipron, Eli Lilly, Allogene, CAR-T, peptides, GLP-1, Q1 earnings, Lilly,AstraZeneca, J&J, GSK, Sanofi, BMS

Daraxonrasib slashes death risk 60% in metastatic pancreaticcancer Phase 3 — Revolution Medicines leads a $1.5B offering wave. Neurocrine acquires Soleno for $2.9B, Regeneron enters radiopharma via Telix, and Travere nabs the first-ever FSGS approval with Filspari.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, daraxonrasib, Revolution Medicines, RVMD, pancreatic cancer, RASolute 302, Neurocrine Biosciences, Soleno Therapeutics, VYKAT XR, Prader-Willi syndrome, Filspari,sparsentan, Travere Therapeutics, FSGS, Regeneron, Telix Pharmaceuticals, radiopharmaceuticals, Eli Lilly, CrossBridge Bio, ADC, antibody-drug conjugate, Jaypirca, pirtobrutinib, CLL, ORIC Pharmaceuticals, rinzimetostat, Zentalis,azenosertib, Allogene, cema-cel, CAR-T, Johnson & Johnson, Icotyde, Spyre Therapeutics, SPY001, ulcerative colitis, Pfizer, Adcetris, Lilly, Roche, AstraZeneca, J&J, Gilead

FDA issues second CRL for Replimune's melanoma therapy RP1 —stock drops 20%, single-arm trial debate sharpens. Sun Pharma's $12B all-cash bid for Organon, Amgen's 77% proptosis response in subcutaneous TEPEZZA Phase 3, Lilly launches Foundayo, and AACR 2026 preview.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Replimune, RP1,vusolimogene oderparepvec, melanoma, complete response letter, Sun Pharma,Organon, acquisition, Amgen, TEPEZZA, teprotumumab, thyroid eye disease, EliLilly, Foundayo, GLP-1, Novo Nordisk, Wegovy, Immunovant, batoclimab, Invivyd,VMS063, measles, AACR 2026, Gilead, Tubulis, ADC, Neurocrine, Soleno, Insmed,brensocatib, Travere, FILSPARI, sparsentan, FSGS, BioNTech, trastuzumabpamirtecan, Merck, Terns Pharmaceuticals, Roche, C4 Therapeutics, Lilly,AstraZeneca

FDA approves Regeneron's Otarmeni — the first gene therapy for genetic hearing loss — as Regeneron closes the 17th and final White House MFN pricing deal. Roche calls giredestrant its potentially largest product ever, Novo Nordisk's 72% decline deepens, AbbVie commits $1.4B to North Carolina.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Regeneron, Otarmeni, gene therapy, hearing loss, FDA approval, MFN pricing, White House, Roche, giredestrant, breast cancer, Novo Nordisk, oral semaglutide, Foundayo, orforglipron, AbbVie, Durham, manufacturing, Rigel, Eli Lilly, RIPK1, Grace Therapeutics, GTX-104, nimodipine, Sanofi, Dupixent, Novartis, radioligand therapy, GE HealthCare, LUMINA, Tempero, Amgen, Inovio, Lilly

Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th deal of 2026; FDA alleges data manipulation behind Amgen's Tavneos; Boehringer survodutide hits 16.6% weight loss in Phase 3.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Erasca, ERAS-0015, pan-RAS, KRAS, AbbVie, Kestrel Therapeutics, Eli Lilly, Ajax Therapeutics, JAKinhibitor, myelofibrosis, Amgen, Tavneos, ChemoCentryx, data manipulation, Intellia Therapeutics, CRISPR, gene editing, BridgeBio, Vyndamax, Pfizer, Boehringer Ingelheim, survodutide, obesity, AstraZeneca, Breztri, asthma,Incyte, vitiligo, Oruka, psoriasis, Veradermics, Sanofi, tolebrutinib, Lilly

Sun Pharma just wrote an eleven-point-seven-five billiondollar check to acquire Organon — the largest outbound pharma acquisition in Indian history, according to Reuters. And Intellia's in vivo CRISPR therapyjust delivered the first Phase 3 win for gene editing inside the body. Big Monday. Let's get into it.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Eli Lilly, Lilly, AstraZeneca, Merck, AbbVie, Regeneron

Lilly's Foundayo logs just 3,707 prescriptions in week two vs. 18,410 for Novo's oral Wegovy — a 5:1 gap that sent Lilly stock tumbling. Inhibrx surges ~39% on Merck-led takeover interest at $53/share. EU backs Sanofi's tolebrutinib for MS despite FDA rejection. FDA issues psychedelics priority review vouchers.

Visit us at www.thepharmacloseout.com

pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Foundayo, orforglipron, Eli Lilly, Novo Nordisk, Wegovy, oral GLP-1, obesity, Inhibrx, INBRX-106, Merck, Merck KGaA, Ono Pharmaceutical, oncology, tolebrutinib, Cenrifki, Sanofi, multiple sclerosis, SPMS, Regeneron, Otarmeni, gene therapy, hearing loss, Compass Pathways, Usona Institute, Transcend Therapeutics, psychedelics, psilocybin, AbbVie, CRL, Novartis, Pluvicto, Kelonia Therapeutics, Intellia, CRISPR, Roche, Moderna, Daiichi Sankyo, Avalyn Pharma, Pfizer, Lilly